Trial · NCT06081244
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
NCT06081244, Phase 3, Recruiting, Women's Cancer Study Group GmbH
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III). Trials, record NCT06081244. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06081244
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
- NCT number
- NCT06081244
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 348 participants, estimated
- Lead sponsor
- Women's Cancer Study Group GmbH
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Sacituzumab govitecan, Pembrolizumab
- First posted
- 2023-10-13
- Last updated
- 2026-08-03
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | pathological complete remission (pCR) | at surgery | no invasive tumour in breast and lymph nodes (ypT0/is and ypN0) |
| Primary | invasive disease-free survival rate (iDFS), | after 3 years | time from date of first diagnosis to any invasive breast cancer event, death or secondary malignancy according to STEEP 2.0 criteria |
| Secondary | Overall survival (OS) | 6 years | time from first diagnosis to death |
| Secondary | distant disease-free survival (dDFS) | after 3 years | distant disease-free survival |
| Secondary | distant disease-free interval (dDFI) | after 3 years | distant disease-free interval |
| Secondary | recurrence-free survival (RFS) | after 3 years | recurrence-free survival |
| Secondary | local recurrence-free survival (LRFS) | after 3 years | local recurrence-free survival |
| Secondary | Breast cancer free interval (BCFI) | after 3 years | Breast cancer free interval |
| Secondary | Health-related Quality of Life: Quality of Life Questionnaire C30 | Baseline to end of cycle 2 (each cycle is 21 days) | change in QLQ-C30-Score; min 0 - max 100 points; the higher the better quality of life |
| Secondary | Health-related Quality of Life: Quality of Life Questionnaire BR45 | Baseline to end of cycle 2 (each cycle is 21 days) | change in BR45-Score; min 0 - max 100 points; the higher points on functional scale the better the function; the higher points on symptom scale the higher the symptomatology. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06081244
GET https://conductscience.org/api/trials/v1/NCT06081244/registered